https://www.selleckchem.com/products/SNS-032.html
Eczema and eczematous reactions induced by interleukin (IL)-17 inhibitors in patients with psoriasis are established adverse events (1), which may be reported as adverse events (AEs) in up to 12.1% patients on anti-IL-17 treatment in controlled clinical trials (2-5). We performed an integrated safety analysis of 13 clinical studies to evaluate the frequency and management of the treatment-emergent adverse events (TE-AEs) of eczema and clinical variants in patients with moderate-to-severe psoriasis treated with ixekizumab (IXE), a select
Like
Comment
Share
